Boron neutron capture therapy (BNCT) is an anti-cancer treatment based on the accumulation in the tumor cells of 10B-containing molecules and subsequent irradiation with low energy neutrons, which bring about the decay of 10B to very toxic 7Li3+ and 4He2+ ions. The effectiveness of BNCT is limited by the low delivery and accumulation of the used 10B-containing compounds. Here we report the development of folic acid-conjugated 4-amino-phenylboronate as a novel possible compound for the selective delivery of 10B in BNCT. An extensive analysis about its biocompatibility to mature blood cells and platelet progenitors revealed that the compound markedly supports platelet aggregation, neutrophil oxidative burst and inhibition of megakaryocyte development, while it does not have any effect on red blood cells.
File in questo prodotto:
Non ci sono file associati a questo prodotto.